Quintet Private Bank Europe S.A. Has $9.12 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Quintet Private Bank Europe S.A. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 359,915 shares of the biopharmaceutical company’s stock after purchasing an additional 23,332 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in Pfizer were worth $9,120,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Rialto Wealth Management LLC bought a new position in Pfizer during the 4th quarter worth $26,000. Clarity Asset Management Inc. bought a new position in Pfizer during the 4th quarter worth $27,000. Gould Capital LLC increased its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the 4th quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Performance

Pfizer stock opened at $24.85 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s 50-day moving average price is $23.01 and its two-hundred day moving average price is $24.97. The stock has a market cap of $141.28 billion, a PE ratio of 17.62, a P/E/G ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the previous year, the business posted $0.82 earnings per share. The business’s revenue for the quarter was down 7.8% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.92%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.